Eli Lilly and

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$15,557,700
$12,728,500
$13,532,800
$11,439,100
Gross Profit
13,109,900
10,504,300
11,129,000
9,268,300
EBITDA
7,503,900
4,162,600
5,748,200
2,247,900
EBIT
7,025,400
3,699,800
5,263,400
1,781,100
Net Income
5,660,500
2,759,300
4,409,800
970,300
Net Change In Cash
15,557,700
12,728,500
13,532,800
11,439,100
Free Cash Flow
1,283,000
-1,600,900
726,600
-458,900
Cash
3,375,900
3,093,300
3,268,400
3,369,000
Basic Shares
899,793
900,604
903,158
905,000

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$45,042,700
$34,124,100
$28,541,400
$28,318,400
Gross Profit
36,624,400
27,041,900
21,911,600
21,005,600
EBITDA
15,227,600
8,567,800
8,660,500
8,042,900
EBIT
13,461,000
7,040,500
7,138,000
6,495,300
Net Income
10,590,000
5,240,400
6,244,800
5,581,700
Net Change In Cash
45,042,700
34,124,100
28,541,400
28,318,400
Cost of Revenue
-1,583,900
Free Cash Flow
414,300
-3,152,000
4,600,400
5,387,500
Cash
3,268,400
2,818,600
2,067,000
3,818,500
Basic Shares
904,059
903,284
950,182
953,653

Earnings Calls

Quarter EPS
2025-06-30
$6.31
2025-03-31
$3.34
2024-12-31
$5.32
2024-09-30
$1.18